Lenalidomide in the Treatment of Multiple Myeloma
Authors:
K. Machálková; V. Maisnar
Authors‘ workplace:
Oddělení klinické hematologie, II. interní klinika LF UK a FN Hradec Králové
Published in:
Klin Onkol 2009; 22(3): 117-120
Category:
Case Reports
Overview
We present the case of a 58-year old patient with relapsed multiple myeloma, in which lenalidomide was used in combination with dexamethasone after the failure of previous treatment modalities. The progression of the myeloma was clinically manifested by painful swelling of the patient’s left arm caused by an extensive osteolytic lesion of the bone. After one month of therapy with lenalidomide and dexamethasone, a significant decrease in the paraprotein level was detected. Later, the clinical finding on the left arm was normalized too and concurrently the X ray image shows the production of new bone.
Key words:
multiple myeloma – treatment – lenalidomide
Sources
1. Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther 2008; 33(3): 219–226.
2. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus Dexamethasone for relapsed or refraktory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.
3. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. N Engl J Med 2007; 357: 2133–2142.
4. Celgene corporation – Summary of Product Characteristics. 92 stran, poslední aktualizace 2. 5. 2008.
5. Cavo M et al. Lenalidomide in relapsed/refraktory multiple myeloma: overall survival. Leukemia Res 2008; 32 (Suppl 1): S12–S19.
6. Cavo M et al. Lenalidomide: towards a new standart in the optima management of multiple myeloma. Leukemia Res 2008; 32 (Suppl 1): S20–S24.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2009 Issue 3
Most read in this issue
- Evaluation of Aromatase Inhibitors’ Side Effects in Clinical and Experimental Studies
- Clostridium Difficile Associated Diarrhoea –Problem of Oncological Patient?
- Use of PET/CT Examination in Head and Neck Cancer Radiotherapy Planning
- New Radiopharmaceuticals and Positron-emission Tomography Applications at the Masaryk Memorial Cancer Institute in Brno